AIM ImmunoTech Inc.
AIM ImmunoTech Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for cancer and viral diseases. Founded in 1983, the company has made significant strides in the immunotherapy sector, particularly with its lead product, Ampligen, which is designed to enhance the immune response against various diseases. With a strong presence in the US and expanding operations internationally, AIM ImmunoTech is committed to advancing its research in immuno-oncology and antiviral treatments. The company has garnered attention for its unique approach to harnessing the body’s immune system, positioning itself as a notable player in the biotechnology industry. AIM ImmunoTech continues to explore new avenues for therapeutic development, aiming to improve patient outcomes and redefine treatment paradigms.
DitchCarbon Score
How does AIM ImmunoTech Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AIM ImmunoTech Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AIM ImmunoTech Inc.'s reported carbon emissions
AIM ImmunoTech Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how AIM ImmunoTech is addressing climate change or contributing to sustainability efforts within the biotechnology sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AIM ImmunoTech Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
